Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Director departure
Quarterly results
Appointed director
Cardiff Oncology, Inc. (TROV) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Investor presentation
Docs: "Pancreatic Cancer and Small Cell Lung Cancer Program Updates Metastatic Pancreatic Ductal Adenocarcinoma",
"Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy Pancreatic Cancer Program"
08/09/2023 8-K Quarterly results
Docs: "CARDIFF ONCOLOGY, INC. CERTIFICATE OF ELIMINATION",
"Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Investor presentation
Docs: "Investor Contact:"
07/24/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/16/2023 4 Smeal Tod (Chief Scientific Officer) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Granted 167,088 options @ $1.72, valued at $287.4k
03/16/2023 4 Levine James E. (CFO) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Granted 197,472 options @ $1.72, valued at $339.7k
03/16/2023 4 Kelemen Vicki (Exec. VP and COO) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Granted 125,520 options @ $1.72, valued at $215.9k
03/16/2023 4 Erlander Mark (CEO) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Granted 482,064 options @ $1.72, valued at $829.2k
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Quarterly results
Docs: "Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update"
03/02/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A CAXTON CORP reports a 2.2% stake in Cardiff Oncology, Inc.
02/09/2023 3 Kabbinavar Fairooz (Chief Medical Officer) has filed a Form 3 on Cardiff Oncology, Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT",
"Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib"
01/26/2023 SC 13G ACORN BIOVENTURES, L.P. reports a 6.4% stake in Cardiff Oncology, Inc.
01/26/2023 SC 13D/A ACORN BIOVENTURES, L.P. reports a 6.4% stake in CARDIFF ONCOLOGY, INC.
11/29/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/11/2022 4 Armitage James O (Director) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Bought 13,000 shares @ $1.5564, valued at $20.2k
10/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "G2 G1 M S PLK1"
09/20/2022 4 White Lale (Director) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Bought 15,000 shares @ $1.635, valued at $24.5k
09/19/2022 4 TANNENBAUM RENEE P (Director) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Bought 6,400 shares @ $1.715, valued at $11k
Bought 3,600 shares @ $1.72, valued at $6.2k
09/19/2022 4 PACE GARY W (Director) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Bought 150,000 shares @ $1.71, valued at $256.5k
09/19/2022 4 Levine James E. (CFO) has filed a Form 4 on Cardiff Oncology, Inc.
Txns: Bought 30,000 shares @ $1.557, valued at $46.7k
09/12/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer at the ESMO Congress 2022 Durable responses to treatment, with a median duration of response of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC",
"Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer , Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates Next trial in RAS-mutated mCRC is a randomized Phase 2 trial to demonstrate onvansertib’s contribution to SoC and position for a possible accelerated approval opportunity&#59; topline data expected in 2H 2024",
"CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING"
09/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy